Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous midbrain dopamine neurons
- Development stage
- Unknown
- Lead developer
- Oryon Cell Therapies
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intracerebral
01
Overview
This investigational autologous cell therapy for Parkinson's disease is being developed by Dr. Penelope J. Hallett and colleagues at McLean Hospital's Neuroregeneration Research Institute in collaboration with Mass General Brigham. The treatment involves a multi-step process where a patient's own blood cells are converted into induced pluripotent stem cells (iPSCs), which are then differentiated into specific midbrain dopaminergic neurons. These neurons are surgically transplanted into the putamen to replace the cells lost to disease-related degeneration. Because the therapy uses the patient's own biological material, it eliminates the need for long-term immunosuppressive treatments. The technology has been licensed to Oryon Cell Therapies and is currently being evaluated in a Phase 1/2a clinical trial to assess safety and preliminary efficacy in restoring dopamine production and signaling.
- Other names
- autologous iPSC-derived dopamine neuronsautologous iPSC-derived midbrain dopamine neurons
Beyond the preview
Go deeper on autologous midbrain dopamine neurons.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous midbrain dopamine neurons.